Retrospective Study of Carfilzomib-Pomalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients in a Tertiary Care Hospital in India

Carfilzomib is a second-in class Proteosome Inhibitor and has been approved for Relapsed/Refractory Multiple Myeloma (RRMM). We retrospectively retrieved and analyzed data of KPd combination both biweekly and weekly regimens at our centre from 1 st August 2017 and 31 st May 2020. Sixty-nine patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Pallavi, Yadav, Neha, Folbs, Bhaarat, Kapoor, Jyotsna, Khushoo, Vishvdeep, Agrawal, Narendra, Ahmed, Rayaz, Bhurani, Dinesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254620/
https://www.ncbi.nlm.nih.gov/pubmed/34248306
http://dx.doi.org/10.1007/s12288-021-01461-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254620/
https://www.ncbi.nlm.nih.gov/pubmed/34248306
http://dx.doi.org/10.1007/s12288-021-01461-6

Ejemplares similares